Guyana will be included in the Coviplasm study, confirms the Regional Health Agency in its letter Pro du jour. Since this weekend, this news has toured social networks which were quick to ignite. Some protested that we take the Guyanese “for guinea pigs”. Beginning of explanation.
What is the Coviplasm study?
This clinical trial involves the transfusion of plasma from recovered Covid-19 patients, containing antibodies to the virus, which could transfer this immunity to a patient with Covid-19. The plasma of people who have recovered from Covid-19 contains these antibodies that their bodies have developed. These antibodies could help patients in the acute phase of the disease to fight the virus.
Targeted samples from the EFS began in April in three regions (Ile-de-France, Grand Est, Bourgogne-Franche-Comté) from the first French patients healed from Covid-19.
« We would like to demonstrate that the administration of plasma significantly reduces the percentage of entry into intensive care in these patients who have risk factors for progression to a severe form, such as high blood pressure or diabetes … “Explains Professor Pierre Tiberghien, in an interview with the Foundation for Medical Research. The latter, who is the initiator and scientific manager of the clinical trial designed with Professor Karine Lacombe, sees in the Coviplasm study “ a beautiful image of solidarity between old patients and new ones! » (sic)
Karine Lacombe (head of the Infectious and Tropical Diseases Department of Saint-Antoine Hospital – AP-HP, Sorbonne University), principal investigator of the study, will arrive in Guyana during the first half of July.
In Guyana, the study is notably followed by Pr Félix Djossou (CHC, Umit), Dr Hatem Kallel (CHC, resuscitation), Dr Pascal Guéguéniat (ARS) and Dr Françoise Maire (French blood establishment).
« The fact that we have a lot of patients in Guyana will advance this research, a research that is really very promising (…), replies Clara de Bort, director of ARS to our colleagues in Guyana La 1ere. Inevitably research on drugs and all important research on the Covid-19, begin to take an interest in our territory. »
It now remains to communicate better with the population, which seems in part to immediately reject this “clinical trial”. Proof, if necessary, that trust in the health authorities is indeed undermined …
– .
